BioCentury | Jul 25, 2019
Translation in Brief

Neoantigens in pediatric ALL could lead to cell-based therapies

Despite low tumor mutation load, strong immune responses against predicted neoantigens suggest opportunities to develop immunotherapies for pediatric acute lymphoblastic leukemia. The oncology field is increasingly turning to neoantigens -- non-self antigens arising from mutations...
BioCentury | Apr 30, 2019
Distillery Therapeutics

RUNX1, RUNX3, CBFB and PMP22 as targets for neurofibromatosis

DISEASE CATEGORY: Cancer INDICATION: Neurofibromatosis Cell culture and mouse studies suggest promoting PMP22 expression, dual RUNX1/RUNX3 inhibition, or inhibiting the interactions of CBFB with RUNX1 and RUNX3 could help treat neurofibromatosis. In mouse neurofibroma Schwann...
BioCentury | Nov 6, 2018
Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays; gene profiling; tissue markers Gene profiling coupled with cell-based assays of patient samples could help predict drug responses in AML patients. In tumor samples from 363 patients, whole-exome sequencing plus genotyping of...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BioCentury | Mar 13, 2018
Preclinical News

CDK6 a potential obesity target

A study published in Nature Communications suggests cyclin dependent kinase 6, a known molecular target for cancer, could also be targeted to treat obesity and metabolic diseases. White adipose tissue (WAT) stores energy in rodents...
BioCentury | Feb 28, 2017
Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient samples, cell culture, and mouse studies suggest inhibiting RUNX1 could help treat AML with FLT3 mutations. In AML patients, RUNX1 expression was higher in leukemia samples from patients with...
BioCentury | Feb 23, 2017
Clinical News

Tumor suppressor RUNX1 and FLT3-ITD induces AML

In a paper published in The Journal of Experimental Medicine , European scientists showed that tumor suppressor runt-related transcription factor 1 (RUNX1) works cooperatively with FMS-like tyrosine kinase 3 (FLT3; CD135)-internal tandem duplication (ITD) mutations to...
BioCentury | Jun 4, 2015
Distillery Techniques

Techniques: Direct conversion of fibroblasts to osteoblasts for bone regeneration

Drug platforms TECHNOLOGY: Cell therapy Fibroblasts directly converted to osteoblasts could be used to promote bone regeneration. The method transformed human gingival fibroblasts to cells that expressed multiple osteoblast-related transcripts using a viral vector encoding...
BioCentury | Apr 16, 2015
Distillery Therapeutics

Therapeutics: Histone deacetylase (HDAC); runt-related transcription factor 3 (RUNX3)

Cancer INDICATION: Cancer; solid tumors In vitro and rodent studies suggest HDAC inhibitors that activate the tumor suppressor RUNX3 could help treat cancer. Chemical synthesis and testing in an HDAC inhibition-induced RUNX3 activation assay of...
BioCentury | Mar 12, 2015
Distillery Therapeutics

Therapeutics: Core-binding factor β subunit (CBFB; CBF-β); myosin heavy chain 11 smooth muscle (MYH11; SMMHC); runt-related transcription factor 1 (RUNX1)

Cancer INDICATION: Acute myelogenous leukemia (AML) In vitro, mouse and patient sample studies suggest a small molecule protein-protein inhibitor could help treat the inv(16) subtype of AML. The subtype is driven by an oncogenic CBFB-SMMHC...
Items per page:
1 - 10 of 16